The FDA Just Made It Way Easier to Clone Your Favorite Biologic
The FDA just gutted one of the most expensive requirements for biosimilar developers, and the timing couldn't be more consequential. With over 100 biologics (worth $232 billion) losing patent protection in the coming years, the rules of the biologics market are about to change dramatically.
For fifteen years, making a copycat version of a blockbuster biologic drug has been one of the most expensive, time-consuming gambles in pharma. You had to run massive clinical trials, sometimes spending $150 million and waiting up to four years, just to prove your knockoff worked as well as the original. Think of it like rebuilding an entire house from scratch to prove it's the same floor plan.
The FDA just handed biosimilar developers a shortcut. And the implications for the biologics market are enormous.
The Old Playbook Is Dead
When Congress created the biosimilar pathway in 2010 (via the catchy-named Biologics Price Competition and Innovation Act), the FDA was cautious. Only one biosimilar had ever been approved in the U.S. The agency essentially told developers: show us the analytics, show us the pharmacokinetics (how the drug moves through the body), and also run a big comparative efficacy trial proving your drug works just as well as the original in real patients.
That last part was the killer. Those comparative trials cost roughly $24 million each and took one to three years. For context, the total PK testing portion of a biosimilar program runs about $40 million, which is around 30% of total development costs. Stack it all up, and you're looking at a brutally expensive ticket to entry.
Now, after reviewing years of real-world data from dozens of approved biosimilars, the FDA has concluded something that many scientists suspected all along: those big efficacy trials were mostly confirming what the lab work already showed. When a biosimilar looks virtually identical under high-resolution analytical testing, it performs virtually identically in patients. The expensive clinical trial was just an echo.
What Actually Changed
The FDA rolled out two major moves. The first came in October 2025, when the agency announced that comparative efficacy studies would no longer be expected for most biosimilars, as long as developers could show robust analytical similarity plus appropriate PK and safety data.
The second came in March 2026, when the FDA issued revised guidance ("Revision 4" of its biosimilar Q&As) that took aim at PK testing requirements too. The highlights:
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Fewer, simpler PK studies. The FDA estimates sponsors could see up to a 50% reduction in PK study costs, saving roughly $20 million per program. The agency wants developers to focus PK work only where it's genuinely informative, not as a box-checking exercise.
No more mandatory three-way comparisons. Previously, if you tested your biosimilar against a European version of the reference drug, you often had to run a three-arm study: your product, the U.S. version, and the European version, all side by side. That requirement is gone. Now, if you can scientifically justify using a non-U.S. comparator (backed by strong analytical data bridging it to the U.S. product), the FDA will accept it.
The 2015 playbook is officially retired. The FDA formally withdrew its original 2015 guidance on demonstrating biosimilarity, acknowledging it no longer reflects the agency's thinking. That document was written when the U.S. had approved exactly one biosimilar. Today, there are dozens.
The FDA also signaled that most non-vaccine biosimilars could eventually be approved as interchangeable by default, meaning pharmacists could substitute them without calling the prescribing doctor. That's a game-changer for adoption.
Follow the Money
This isn't just regulatory housekeeping. It's a market-reshaping event.
Consider the scale: around 15-20 major biologics are expected to lose patent exclusivity in the coming years. The FDA itself notes that biologics account for roughly 5% of U.S. prescriptions but a staggering 50% of drug spending. And here's the kicker: only about 10% of those biologics losing protection currently have biosimilars in development.
That gap exists partly because the old pathway was so expensive. Slash the cost of entry, and suddenly marginal projects become viable. More developers jump in. More molecules get competition.
We already have a preview of what that looks like. The FDA approved 18 biosimilars in 2025 alone, including copycat versions of denosumab (the bone drug sold as Prolia and Xgeva), ustekinumab (the blockbuster immunology drug Stelara), and insulin aspart (the rapid-acting insulin NovoLog). Two of those 18 were the first-ever biosimilars for their respective reference products.
Winners and Losers
The biggest winners here are companies that play both sides of the fence. Amgen, for instance, is simultaneously an innovator with its own biologic franchises and one of the largest biosimilar developers in the world. Lower development costs improve the economics of every biosimilar program in its pipeline. Analysts broadly view Amgen as a net beneficiary.
Pure-play innovators face a trickier calculus. AbbVie already lived through the Humira biosimilar onslaught (biosimilars now sell at discounts up to 92% off the brand's list price). The new guidance doesn't change that history, but it does raise a red flag for future blockbusters like Skyrizi and Rinvoq: expect denser, faster biosimilar competition once those drugs lose exclusivity.
Roche knows this movie well. Its legacy oncology biologics (Herceptin, Avastin, Rituxan) already face heavy biosimilar pressure. Six Herceptin biosimilars have driven significant price drops since 2019. With oncologists being among the most biosimilar-friendly prescribers, the pricing power on any "plain vanilla" monoclonal antibody is shrinking fast.
The Billion-Dollar Blockbusters in the Crosshairs
The next few years will test this new framework on some of pharma's crown jewels. Keytruda, Merck's mega-blockbuster cancer immunotherapy with over $20 billion in annual global sales, faces core patent expirations starting around 2028. Multiple biosimilar programs are already underway. Under the old rules, each of those developers would need a massive, expensive efficacy trial. Under the new rules, strong analytical and PK data might be enough.
Stelara (roughly $10-11 billion in global sales) is losing U.S. protection now. Perjeta ($4.3 billion globally) follows close behind. Repatha, Amgen's own cholesterol-lowering antibody, hits its patent cliff around 2028.
What It All Means
The FDA is essentially telling the biologics industry: the era of using regulatory complexity as a competitive moat is ending. The agency wants more biosimilars, for more drugs, entering the market faster. It's replacing expensive clinical redundancy with precision analytics.
For patients, this should eventually mean lower prices on some of medicine's most expensive therapies. For innovators, it means the window to extract premium pricing from a biologic franchise just got shorter. And for biosimilar developers, the math on entering the market just got a whole lot more attractive.
The big question is whether cheaper, faster approvals will actually translate into cheaper drugs at the pharmacy counter. If the Humira experience is any guide, it takes multiple competitors and aggressive payer behavior to drive real savings. But the FDA just removed one of the biggest barriers to making that happen.
Deals & M&A
4 min read
The Italian Family That Just Spent $4.1 Billion to Break Into America
A 107-year-old Italian family pharma just dropped $4.1 billion on a Florida rare disease company, paying roughly three times its own annual revenue. The deal gives Angelini instant access to the U.S. market and a portfolio generating nearly $600 million a year.
